Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Maria Vittoria Dieci, Nina Radosevic-Robin, Susan A. Fineberg, Gert van den Eynden, Nils Ternes, Frederique Penault-Llorca, Giancarlo Pruneri, Timothy M. D'Alfonso, Sandra Demaria, Carlos Castaneda, Joselyn Sanchez, Sunil Badve, Stefan Michiels, Veerle Bossuyt, Federico Rojo, Baljit Singh, Torsten Nielsen, Giuseppe Viale, Seong Rim Kim, Stephen HewittStephan Wienert, Sybille Loibl, David Rimm, Fraser Symmans, Carsten Denkert, Sylvia Adams, Sherene Loi, Roberto Salgado

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

Original languageEnglish (US)
JournalSeminars in Cancer Biology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Tumor-Infiltrating Lymphocytes
Neoadjuvant Therapy
Carcinoma in Situ
Biomarkers
Breast Neoplasms
Carcinoma, Intraductal, Noninfiltrating
Research Personnel
Clinical Trials
Guidelines
Carcinoma
Drug Therapy
Research

Keywords

  • Breast cancer
  • Ductal carcinoma in situ
  • Neoadjuvant
  • Residual cancer burden
  • Residual disease
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. / Dieci, Maria Vittoria; Radosevic-Robin, Nina; Fineberg, Susan A.; van den Eynden, Gert; Ternes, Nils; Penault-Llorca, Frederique; Pruneri, Giancarlo; D'Alfonso, Timothy M.; Demaria, Sandra; Castaneda, Carlos; Sanchez, Joselyn; Badve, Sunil; Michiels, Stefan; Bossuyt, Veerle; Rojo, Federico; Singh, Baljit; Nielsen, Torsten; Viale, Giuseppe; Kim, Seong Rim; Hewitt, Stephen; Wienert, Stephan; Loibl, Sybille; Rimm, David; Symmans, Fraser; Denkert, Carsten; Adams, Sylvia; Loi, Sherene; Salgado, Roberto.

In: Seminars in Cancer Biology, 01.01.2017.

Research output: Contribution to journalArticle

Dieci, MV, Radosevic-Robin, N, Fineberg, SA, van den Eynden, G, Ternes, N, Penault-Llorca, F, Pruneri, G, D'Alfonso, TM, Demaria, S, Castaneda, C, Sanchez, J, Badve, S, Michiels, S, Bossuyt, V, Rojo, F, Singh, B, Nielsen, T, Viale, G, Kim, SR, Hewitt, S, Wienert, S, Loibl, S, Rimm, D, Symmans, F, Denkert, C, Adams, S, Loi, S & Salgado, R 2017, 'Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer', Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2017.10.003
Dieci, Maria Vittoria ; Radosevic-Robin, Nina ; Fineberg, Susan A. ; van den Eynden, Gert ; Ternes, Nils ; Penault-Llorca, Frederique ; Pruneri, Giancarlo ; D'Alfonso, Timothy M. ; Demaria, Sandra ; Castaneda, Carlos ; Sanchez, Joselyn ; Badve, Sunil ; Michiels, Stefan ; Bossuyt, Veerle ; Rojo, Federico ; Singh, Baljit ; Nielsen, Torsten ; Viale, Giuseppe ; Kim, Seong Rim ; Hewitt, Stephen ; Wienert, Stephan ; Loibl, Sybille ; Rimm, David ; Symmans, Fraser ; Denkert, Carsten ; Adams, Sylvia ; Loi, Sherene ; Salgado, Roberto. / Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ : A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. In: Seminars in Cancer Biology. 2017.
@article{f43927371ca14c5ca9991e58e12f373e,
title = "Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer",
abstract = "Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.",
keywords = "Breast cancer, Ductal carcinoma in situ, Neoadjuvant, Residual cancer burden, Residual disease, Tumor-infiltrating lymphocytes",
author = "Dieci, {Maria Vittoria} and Nina Radosevic-Robin and Fineberg, {Susan A.} and {van den Eynden}, Gert and Nils Ternes and Frederique Penault-Llorca and Giancarlo Pruneri and D'Alfonso, {Timothy M.} and Sandra Demaria and Carlos Castaneda and Joselyn Sanchez and Sunil Badve and Stefan Michiels and Veerle Bossuyt and Federico Rojo and Baljit Singh and Torsten Nielsen and Giuseppe Viale and Kim, {Seong Rim} and Stephen Hewitt and Stephan Wienert and Sybille Loibl and David Rimm and Fraser Symmans and Carsten Denkert and Sylvia Adams and Sherene Loi and Roberto Salgado",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.semcancer.2017.10.003",
language = "English (US)",
journal = "Seminars in Cancer Biology",
issn = "1044-579X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ

T2 - A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

AU - Dieci, Maria Vittoria

AU - Radosevic-Robin, Nina

AU - Fineberg, Susan A.

AU - van den Eynden, Gert

AU - Ternes, Nils

AU - Penault-Llorca, Frederique

AU - Pruneri, Giancarlo

AU - D'Alfonso, Timothy M.

AU - Demaria, Sandra

AU - Castaneda, Carlos

AU - Sanchez, Joselyn

AU - Badve, Sunil

AU - Michiels, Stefan

AU - Bossuyt, Veerle

AU - Rojo, Federico

AU - Singh, Baljit

AU - Nielsen, Torsten

AU - Viale, Giuseppe

AU - Kim, Seong Rim

AU - Hewitt, Stephen

AU - Wienert, Stephan

AU - Loibl, Sybille

AU - Rimm, David

AU - Symmans, Fraser

AU - Denkert, Carsten

AU - Adams, Sylvia

AU - Loi, Sherene

AU - Salgado, Roberto

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

AB - Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

KW - Breast cancer

KW - Ductal carcinoma in situ

KW - Neoadjuvant

KW - Residual cancer burden

KW - Residual disease

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85035012871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035012871&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2017.10.003

DO - 10.1016/j.semcancer.2017.10.003

M3 - Article

C2 - 29024776

AN - SCOPUS:85035012871

JO - Seminars in Cancer Biology

JF - Seminars in Cancer Biology

SN - 1044-579X

ER -